세계의 위암 시장 보고서(2025년)

Gastric Cancer Global Market Report 2025

US $ 4,490 ￦ 6,242,000

PDF (Single User License)

PDF 보고서를 1명만 이용할 수 있는 라이선스입니다. 인쇄 가능하며 인쇄물의 이용 범위는 PDF 이용 범위와 동일합니다.

US $ 6,490 ￦ 9,023,000

PDF (Site License)

PDF 보고서를 동일 사업장의 모든 분이 이용할 수 있는 라이선스입니다. 인쇄 가능하며 인쇄물의 이용 범위는 PDF 이용 범위와 동일합니다.

US $ 8,490 ￦ 11,803,000

PDF (Enterprise License)

PDF 보고서를 동일 기업의 모든 분이 이용할 수 있는 라이선스입니다. 인쇄 가능하며 인쇄물의 이용 범위는 PDF 이용 범위와 동일합니다.

한글목차

위암 시장 규모는 향후 몇 년 동안 빠르게 성장할 것으로 예상되며, 2029년에는 연평균 15.2%의 성장률로 64억 3,000만 달러에 달할 것으로 예측됩니다. 예측 기간 동안 비만율 증가, 정부 이니셔티브 증가, 헬스케어 투자 증가, 경구용 약물에 대한 수요 증가, 암 치료 시설의 확대 등으로 인해 성장이 예상됩니다. 이 기간의 주요 동향으로는 병용 화학요법, 제품 확대, 로봇 보조 수술, 표적 치료, 전략적 제휴, 첨단 진단 도구 개발 등을 들 수 있습니다.

비만율 증가가 향후 위암 시장 확대를 견인할 것으로 예측됩니다. 비만은 체지방이 과도하게 축적된 것을 특징으로 하는 질환으로 체질량지수(BMI) 30 이상으로 정의되며, 다양한 건강상의 합병증을 유발할 수 있습니다. 비만율 증가는 식습관 장애, 운동 부족, 좌식 생활습관, 환경적 영향, 유전적 요인 등의 요인에 기인합니다. 과도한 체지방, 특히 복부 주변의 내장지방은 위암 발병 위험을 증가시킵니다. 비만은 만성 염증과 대사 불균형을 유발하고, 둘 다 암 발생과 관련이 있기 때문에 위암 치료에 대한 수요가 증가합니다. 예를 들어, 세계보건기구(WHO)는 2024년 3월, 2022년에는 전 세계 인구 8명 중 1명이 비만을 앓고 있으며, 18세 이상 성인의 약 25억 명이 과체중으로 간주되고, 8억 9,000만 명이 비만으로 분류된다고 보고했습니다. 성인의 43%가 과체중, 16%가 비만인 것으로 나타났습니다. 또한 5세 미만 어린이 3,700만 명이 과체중이고, 5-19세 어린이와 청소년 3억 9,000만 명 이상이 과체중이며, 이 중 1억 6,000만 명이 비만과 공존하고 있습니다. 그 결과, 비만율 증가는 위암 치료에 대한 수요를 증가시키고 있습니다.

위암 시장의 주요 기업들은 맞춤형 치료를 보장하기 위해 동반진단 분석과 같은 첨단 솔루션 개발에 주력하고 있습니다. 2024년 10월, 스위스에 본사를 둔 제약회사 F. Hoffman-La Roche는 미국 식품의약국(FDA)으로부터 VENTANA CLDN18(43-14A) RxDx Assay를 승인받았습니다.) RxDx Assay의 승인을 받았습니다. 이는 위 및 위식도 접합부(GEJ) 선암에서 CLDN18 단백질 발현을 평가하는 최초의 면역조직화학(IHC) 동반 진단법입니다. 이 검사는 CLDN18 단백질 변이체, 특히 CLDN18.2를 검출하여 VYLOY(졸베툭시맙)의 표적치료 대상 환자를 선별합니다. 이 검사는 BenchMark ULTRA 장비에서 OptiView DAB IHC 검출 키트를 사용하여 개인 맞춤형 의료를 촉진하고 위암 및 GEJ 선암 환자의 치료 옵션을 확대합니다.

목차

제1장 주요 요약

제2장 시장 특징

제3장 시장 동향과 전략

제4장 시장 - 거시경제 시나리오 금리, 인플레이션, 지정학, 신형 코로나바이러스 영향과 회복이 시장에 미치는 영향을 포함한 거시경제 시나리오

제5장 세계의 성장 분석과 전략 분석 프레임워크

• 세계 위암 PESTEL 분석(정치, 사회, 기술, 환경, 법적 요인, 촉진요인과 억제요인)
• 최종 이용 산업 분석
• 세계의 위암 시장 : 성장률 분석
• 세계의 위암 시장 실적 : 규모와 성장, 2019-2024
• 세계의 위암 시장 예측 : 규모와 성장, 2024-2029, 2034F
• 세계 위암 전체 시장(TAM)

제6장 시장 세분화

• 세계의 위암 시장 : 유형별, 분석과 예측, 2019-2024, 2024-2029F, 2034F
• 선암
• 림프종
• 위장관 기질종양
• 카르티노이드 종양
• 기타 유형
• 세계의 위암 시장 : 진단별, 분석과 예측, 2019-2024, 2024-2029F, 2034F
• 내시경 검사
• 생검
• 영상 검사
• 탐색 수술
• 기타 진단
• 세계의 위암 시장 : 치료별, 분석과 예측, 2019-2024, 2024-2029F, 2034F
• 수술
• 방사선 치료
• 화학요법
• 표적치료
• 완화의료
• 기타 치료법
• 세계의 위암 시장 : 유통 채널별, 분석과 예측, 2019-2024, 2024-2029F, 2034F
• 병원 약국
• 전문 약국 및 소매 약국
• 기타 유통 채널
• 세계의 위암 시장 : 선암별, 분석과 예측, 2019-2024, 2024-2029F, 2034F
• 장형선암
• 미만형 선암
• 혼합형 선암
• 세계의 위암 시장 : 림프종별, 분석과 예측, 2019-2024, 2024-2029F, 2034F
• 원발성 위 림프종
• 2차성 위 림프종
• 세계의 위암 시장 : 위장관 기질종양(GIST)별, 분석과 예측, 2019-2024, 2024-2029F, 2034F
• 원발성 GIST
• 전이성 GIST
• 세계의 위암 시장 : 카르티노이드 종양별, 분석과 예측, 2019-2024, 2024-2029F, 2034F
• 위카르티노이드 1형
• 위카르티노이드 2형
• 위카르티노이드 3형
• 세계의 위암 시장 : 기타 유형별, 분석과 예측, 2019-2024, 2024-2029F, 2034F
• 소세포암
• 편평상피암
• 혼합 종양

제7장 지역별/국가별 분석

• 세계의 위암 시장 : 지역별, 분석과 예측, 2019-2024, 2024-2029F, 2034F
• 세계의 위암 시장 : 국가별, 분석과 예측, 2019-2024, 2024-2029F, 2034F

제8장 아시아태평양 시장

제9장 중국 시장

제10장 인도 시장

제11장 일본 시장

제12장 호주 시장

제13장 인도네시아 시장

제14장 한국 시장

제15장 서유럽 시장

제16장 영국 시장

제17장 독일 시장

제18장 프랑스 시장

제19장 이탈리아 시장

제20장 스페인 시장

제21장 동유럽 시장

제22장 러시아 시장

제23장 북미 시장

제24장 미국 시장

제25장 캐나다 시장

제26장 남미 시장

제27장 브라질 시장

제28장 중동 시장

제29장 아프리카 시장

제30장 경쟁 구도와 기업 개요

• 위암 시장 : 경쟁 구도
• 위암 시장 : 기업 개요
  • F. Hoffmann La Roche Ltd. Overview, Products and Services, Strategy and Financial Analysis
  • Merck And Co. Inc. Overview, Products and Services, Strategy and Financial Analysis
  • AbbVie Inc. Overview, Products and Services, Strategy and Financial Analysis
  • Sanofi S.A. Overview, Products and Services, Strategy and Financial Analysis
  • Bristol Myers Squibb Company Overview, Products and Services, Strategy and Financial Analysis

제31장 기타 주요 기업 및 혁신 기업

• Abbott Laboratories
• Novartis AG
• GlaxoSmithKline Plc
• Eli Lilly and Company
• Amgen Inc.
• Gilead Sciences Inc.
• Teva Pharmaceutical Industries Ltd.
• Boehringer Ingelheim
• Astellas Pharma Inc.
• Daiichi Sankyo Company Limited
• Eisai Co. Ltd.
• Ipsen Biopharmaceuticals Inc.
• Ono Pharmaceutical Co. Ltd.
• Samsung Biologics Co. Ltd.
• Celltrion Healthcare Co. Ltd.

제32장 세계 시장 경쟁 벤치마킹과 대시보드

제33장 주요 인수합병(M&A)

제34장 최근 시장 동향

제35장 시장 잠재력이 높은 국가, 부문, 전략

• 위암 시장(2029년) : 새로운 기회를 제공하는 국가
• 위암 시장(2029년) : 새로운 기회를 제공하는 부문
• 위암 시장(2029년) : 성장 전략
  • 시장 동향에 근거한 전략
  • 경쟁 전략

제36장 부록

LSH

영문 목차

영문목차

Gastric cancer is a malignant tumor that begins in the stomach lining, often starting in the mucosa, the innermost layer of the stomach. If left untreated, it can spread to deeper layers, surrounding tissues, or distant organs. Common risk factors for the disease include chronic infection with Helicobacter pylori, smoking, heavy alcohol consumption, an unhealthy diet, and genetic factors.

The main types of gastric cancers include adenocarcinoma, lymphoma, gastrointestinal stromal tumors, carcinoid tumors, and others. Adenocarcinoma, the most prevalent type, originates in the glandular cells of the stomach lining. Diagnosis is typically made through endoscopy, biopsy, imaging tests, exploratory surgery, and other methods. Treatment options include surgery, radiation therapy, chemotherapy, targeted therapy, palliative care, and more. These treatments are distributed through various channels, including hospital pharmacies, specialty and retail pharmacies, among others.

The gastric cancer market research report is one of a series of new reports from The Business Research Company that provides gastric cancer market statistics, including gastric cancer industry global market size, regional shares, competitors with a gastric cancer market share, detailed gastric cancer market segments, market trends and opportunities, and any further data you may need to thrive in the gastric cancer industry. This gastric cancer market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenario of the industry.

The gastric cancer market size has grown rapidly in recent years. It will grow from $3.17 billion in 2024 to $3.65 billion in 2025 at a compound annual growth rate (CAGR) of 15.4%. The growth during the historic period can be attributed to factors such as an increasing geriatric population, rising healthcare awareness, a growing number of genetic mutations, the adoption of unhealthy lifestyles, and heightened awareness about cancer.

The gastric cancer market size is expected to see rapid growth in the next few years. It will grow to $6.43 billion in 2029 at a compound annual growth rate (CAGR) of 15.2%. In the forecast period, growth is expected due to rising obesity rates, growing government initiatives, increased healthcare investments, a higher demand for oral drugs, and the expanding number of cancer treatment facilities. Key trends during this period include combination chemotherapy, product expansion, robotic-assisted surgery, targeted therapies, strategic collaborations, and the development of advanced diagnostic tools.

The growing rates of obesity are expected to drive the expansion of the gastric cancer market in the future. Obesity is a medical condition characterized by excessive body fat, often defined by a body mass index (BMI) of 30 or higher, which can lead to various health complications. The increase in obesity rates can be attributed to factors such as poor dietary habits, lack of exercise, sedentary lifestyles, environmental influences, and genetic factors. Excess body fat, especially visceral fat around the abdomen, is linked to an elevated risk of developing gastric cancer. Obesity causes chronic inflammation and metabolic imbalances, both of which are associated with cancer development, thereby contributing to a higher demand for gastric cancer treatments. For example, the World Health Organization reported in March 2024 that approximately 1 in 8 people globally were living with obesity in 2022. Around 2.5 billion adults aged 18 and older were considered overweight, with 890 million classified as obese. Among adults, 43% were overweight, and 16% were obese. Additionally, 37 million children under 5 were overweight, and more than 390 million children and adolescents aged 5-19 were overweight, including 160 million living with obesity. As a result, rising obesity rates are fueling the demand for gastric cancer treatments.

Leading companies in the gastric cancer market are focused on developing advanced solutions, such as companion diagnostic assays, to ensure personalized treatment. Companion diagnostic assays are tests that identify patients likely to benefit from specific treatments based on certain biomarkers. In October 2024, F. Hoffmann-La Roche Ltd., a pharmaceutical company based in Switzerland, received approval from the U.S. Food and Drug Administration (FDA) for the VENTANA CLDN18 (43-14A) RxDx Assay. This was the first immunohistochemistry (IHC) companion diagnostic for assessing CLDN18 protein expression in gastric and gastroesophageal junction (GEJ) adenocarcinoma. The assay identifies patients eligible for targeted treatment with VYLOY (zolbetuximab) by detecting CLDN18 protein variants, particularly CLDN18.2. This test utilizes the OptiView DAB IHC Detection Kit on the BenchMark ULTRA instrument, advancing personalized healthcare and expanding treatment options for gastric and GEJ adenocarcinoma patients.

In June 2022, Panbela Therapeutics Inc., a US-based biopharmaceutical company, acquired Cancer Prevention Pharmaceuticals Inc. for an undisclosed amount. This acquisition allows Panbela Therapeutics to diversify its pipeline and address multiple therapeutic areas. The deal adds four clinical-stage assets, including two late-stage registration assets, enhancing the combined entity's potential. This strategic move strengthens Panbela's position in high-potential therapeutic areas. Cancer Prevention Pharmaceuticals Inc. is a biotechnology company in the US that develops therapeutics for gastric cancer treatment.

Major players in the gastric cancer market are F. Hoffmann La Roche Ltd., Merck And Co. Inc., AbbVie Inc., Sanofi S.A., Bristol Myers Squibb Company, Abbott Laboratories, Novartis AG, GlaxoSmithKline Plc, Eli Lilly and Company, Amgen Inc., Gilead Sciences Inc., Teva Pharmaceutical Industries Ltd., Boehringer Ingelheim, Astellas Pharma Inc., Daiichi Sankyo Company Limited, Eisai Co. Ltd., Ipsen Biopharmaceuticals Inc., Ono Pharmaceutical Co. Ltd., Samsung Biologics Co. Ltd., Celltrion Healthcare Co. Ltd., Biocon Limited, Hanmi Pharmaceuticals, Mylan N.V., Taiho Oncology Inc., Hikma Pharmaceuticals PLC, Taiho Pharmaceuticals Co. Ltd., and AROG Pharmaceuticals Inc.

North America was the largest region in the gastric cancer market in 2024. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in gastric cancer report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East and Africa.

The countries covered in the gastric cancer market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Russia, South Korea, UK, USA, Canada, Italy, Spain.

The gastric cancer market consists of revenues earned by entities by providing services such as cancer screening and early detection, genetic testing, personalized treatment planning, and research and development services. The market value includes the value of related goods sold by the service provider or included within the service offering. The gastric cancer market also includes sales of chemotherapeutic drugs, radiation therapy equipment, nutritional support products, surgical tools, and instruments. Values in this market are 'factory gate' values, that is the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD, unless otherwise specified).

The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.

Gastric Cancer Global Market Report 2025 from The Business Research Company provides strategists, marketers and senior management with the critical information they need to assess the market.

This report focuses on gastric cancer market which is experiencing strong growth. The report gives a guide to the trends which will be shaping the market over the next ten years and beyond.

Reasons to Purchase

• Gain a truly global perspective with the most comprehensive report available on this market covering 15 geographies.
• Assess the impact of key macro factors such as conflict, pandemic and recovery, inflation and interest rate environment and the 2nd Trump presidency.
• Create regional and country strategies on the basis of local data and analysis.
• Identify growth segments for investment.
• Outperform competitors using forecast data and the drivers and trends shaping the market.
• Understand customers based on the latest market shares.
• Benchmark performance against key competitors.
• Suitable for supporting your internal and external presentations with reliable high quality data and analysis
• Report will be updated with the latest data and delivered to you within 2-3 working days of order along with an Excel data sheet for easy data extraction and analysis.
• All data from the report will also be delivered in an excel dashboard format.

Where is the largest and fastest growing market for gastric cancer ? How does the market relate to the overall economy, demography and other similar markets? What forces will shape the market going forward? The gastric cancer market global report from the Business Research Company answers all these questions and many more.

The report covers market characteristics, size and growth, segmentation, regional and country breakdowns, competitive landscape, market shares, trends and strategies for this market. It traces the market's historic and forecast market growth by geography.

• The market characteristics section of the report defines and explains the market.
• The market size section gives the market size ($b) covering both the historic growth of the market, and forecasting its development.
• The forecasts are made after considering the major factors currently impacting the market. These include:

The forecasts are made after considering the major factors currently impacting the market. These include the Russia-Ukraine war, rising inflation, higher interest rates, and the legacy of the COVID-19 pandemic.

• Market segmentations break down the market into sub markets.
• The regional and country breakdowns section gives an analysis of the market in each geography and the size of the market by geography and compares their historic and forecast growth. It covers the growth trajectory of COVID-19 for all regions, key developed countries and major emerging markets.
• The competitive landscape chapter gives a description of the competitive nature of the market, market shares, and a description of the leading companies. Key financial deals which have shaped the market in recent years are identified.
• The trends and strategies section analyses the shape of the market as it emerges from the crisis and suggests how companies can grow as the market recovers.

Scope

• Markets Covered:1) By Type: Adenocarcinoma; Lymphoma; Gastrointestinal Stromal Tumor; Carcinoid Tumor; Other Types
• 2) By Diagnosis: Endoscopy; Biopsy; Imaging Tests; Exploratory Surgery; Other Diagnosis
• 3) By Treatment: Surgery; Radiation Therapy; Chemotherapy; Targeted Therapy; Palliative Care; Other Treatments
• 4) By Distribution Channel: Hospital Pharmacies; Specialty And Retail Pharmacies; Other Distribution Channels
• Subsegments:
• 1) By Adenocarcinoma: Intestinal Type Adenocarcinoma; Diffuse Type Adenocarcinoma; Mixed Type Adenocarcinoma
• 2) By Lymphoma: Primary Gastric Lymphoma; Secondary Gastric Lymphoma
• 3) By Gastrointestinal Stromal Tumor (GIST): Primary GIST; Metastatic GIST
• 4) By Carcinoid Tumor: Gastric Carcinoid Type 1; Gastric Carcinoid Type 2; Gastric Carcinoid Type 3
• 5) By Other Types: Small Cell Carcinoma; Squamous Cell Carcinoma; Mixed Tumors
• Companies Mentioned: F. Hoffmann La Roche Ltd.; Merck And Co. Inc.; AbbVie Inc.; Sanofi S.A.; Bristol Myers Squibb Company
• Countries: Australia; Brazil; China; France; Germany; India; Indonesia; Japan; Russia; South Korea; UK; USA; Canada; Italy; Spain
• Regions: Asia-Pacific; Western Europe; Eastern Europe; North America; South America; Middle East; Africa
• Time series: Five years historic and ten years forecast.
• Data: Ratios of market size and growth to related markets, GDP proportions, expenditure per capita,
• Data segmentations: country and regional historic and forecast data, market share of competitors, market segments.
• Sourcing and Referencing: Data and analysis throughout the report is sourced using end notes.
• Delivery format: PDF, Word and Excel Data Dashboard.

Table of Contents

1. Executive Summary

2. Gastric Cancer Market Characteristics

3. Gastric Cancer Market Trends And Strategies

4. Gastric Cancer Market - Macro Economic Scenario Macro Economic Scenario Including The Impact Of Interest Rates, Inflation, Geopolitics And Covid And Recovery On The Market

5. Global Gastric Cancer Growth Analysis And Strategic Analysis Framework

• 5.1. Global Gastric Cancer PESTEL Analysis (Political, Social, Technological, Environmental and Legal Factors, Drivers and Restraints)
• 5.2. Analysis Of End Use Industries
• 5.3. Global Gastric Cancer Market Growth Rate Analysis
• 5.4. Global Gastric Cancer Historic Market Size and Growth, 2019 - 2024, Value ($ Billion)
• 5.5. Global Gastric Cancer Forecast Market Size and Growth, 2024 - 2029, 2034F, Value ($ Billion)
• 5.6. Global Gastric Cancer Total Addressable Market (TAM)

6. Gastric Cancer Market Segmentation

• 6.1. Global Gastric Cancer Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• Adenocarcinoma
• Lymphoma
• Gastrointestinal Stromal Tumor
• Carcinoid Tumor
• Other Types
• 6.2. Global Gastric Cancer Market, Segmentation By Diagnosis, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• Endoscopy
• Biopsy
• Imaging Tests
• Exploratory Surgery
• Other Diagnosis
• 6.3. Global Gastric Cancer Market, Segmentation By Treatment, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• Surgery
• Radiation Therapy
• Chemotherapy
• Targeted Therapy
• Palliative Care
• Other Treatments
• 6.4. Global Gastric Cancer Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• Hospital Pharmacies
• Specialty And Retail Pharmacies
• Other Distribution Channels
• 6.5. Global Gastric Cancer Market, Sub-Segmentation Of Adenocarcinoma, By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• Intestinal Type Adenocarcinoma
• Diffuse Type Adenocarcinoma
• Mixed Type Adenocarcinoma
• 6.6. Global Gastric Cancer Market, Sub-Segmentation Of Lymphoma, By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• Primary Gastric Lymphoma
• Secondary Gastric Lymphoma
• 6.7. Global Gastric Cancer Market, Sub-Segmentation Of Gastrointestinal Stromal Tumor (GIST), By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• Primary GIST
• Metastatic GIST
• 6.8. Global Gastric Cancer Market, Sub-Segmentation Of Carcinoid Tumor, By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• Gastric Carcinoid Type 1
• Gastric Carcinoid Type 2
• Gastric Carcinoid Type 3
• 6.9. Global Gastric Cancer Market, Sub-Segmentation Of Other Types, By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• Small Cell Carcinoma
• Squamous Cell Carcinoma
• Mixed Tumors

7. Gastric Cancer Market Regional And Country Analysis

• 7.1. Global Gastric Cancer Market, Split By Region, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 7.2. Global Gastric Cancer Market, Split By Country, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

8. Asia-Pacific Gastric Cancer Market

• 8.1. Asia-Pacific Gastric Cancer Market Overview
• Region Information, Market Information, Background Information, Government Initiatives, Regulations, Regulatory Bodies, Major Associations, Taxes Levied, Corporate Tax Structure, Investments, Major Companies
• 8.2. Asia-Pacific Gastric Cancer Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 8.3. Asia-Pacific Gastric Cancer Market, Segmentation By Diagnosis, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 8.4. Asia-Pacific Gastric Cancer Market, Segmentation By Treatment, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

9. China Gastric Cancer Market

• 9.1. China Gastric Cancer Market Overview
• 9.2. China Gastric Cancer Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F,$ Billion
• 9.3. China Gastric Cancer Market, Segmentation By Diagnosis, Historic and Forecast, 2019-2024, 2024-2029F, 2034F,$ Billion
• 9.4. China Gastric Cancer Market, Segmentation By Treatment, Historic and Forecast, 2019-2024, 2024-2029F, 2034F,$ Billion

10. India Gastric Cancer Market

• 10.1. India Gastric Cancer Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 10.2. India Gastric Cancer Market, Segmentation By Diagnosis, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 10.3. India Gastric Cancer Market, Segmentation By Treatment, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

11. Japan Gastric Cancer Market

• 11.1. Japan Gastric Cancer Market Overview
• 11.2. Japan Gastric Cancer Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 11.3. Japan Gastric Cancer Market, Segmentation By Diagnosis, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 11.4. Japan Gastric Cancer Market, Segmentation By Treatment, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

12. Australia Gastric Cancer Market

• 12.1. Australia Gastric Cancer Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 12.2. Australia Gastric Cancer Market, Segmentation By Diagnosis, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 12.3. Australia Gastric Cancer Market, Segmentation By Treatment, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

13. Indonesia Gastric Cancer Market

• 13.1. Indonesia Gastric Cancer Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 13.2. Indonesia Gastric Cancer Market, Segmentation By Diagnosis, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 13.3. Indonesia Gastric Cancer Market, Segmentation By Treatment, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

14. South Korea Gastric Cancer Market

• 14.1. South Korea Gastric Cancer Market Overview
• 14.2. South Korea Gastric Cancer Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 14.3. South Korea Gastric Cancer Market, Segmentation By Diagnosis, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 14.4. South Korea Gastric Cancer Market, Segmentation By Treatment, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

15. Western Europe Gastric Cancer Market

• 15.1. Western Europe Gastric Cancer Market Overview
• 15.2. Western Europe Gastric Cancer Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 15.3. Western Europe Gastric Cancer Market, Segmentation By Diagnosis, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 15.4. Western Europe Gastric Cancer Market, Segmentation By Treatment, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

16. UK Gastric Cancer Market

• 16.1. UK Gastric Cancer Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 16.2. UK Gastric Cancer Market, Segmentation By Diagnosis, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 16.3. UK Gastric Cancer Market, Segmentation By Treatment, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

17. Germany Gastric Cancer Market

• 17.1. Germany Gastric Cancer Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 17.2. Germany Gastric Cancer Market, Segmentation By Diagnosis, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 17.3. Germany Gastric Cancer Market, Segmentation By Treatment, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

18. France Gastric Cancer Market

• 18.1. France Gastric Cancer Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 18.2. France Gastric Cancer Market, Segmentation By Diagnosis, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 18.3. France Gastric Cancer Market, Segmentation By Treatment, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

19. Italy Gastric Cancer Market

• 19.1. Italy Gastric Cancer Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 19.2. Italy Gastric Cancer Market, Segmentation By Diagnosis, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 19.3. Italy Gastric Cancer Market, Segmentation By Treatment, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

20. Spain Gastric Cancer Market

• 20.1. Spain Gastric Cancer Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 20.2. Spain Gastric Cancer Market, Segmentation By Diagnosis, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 20.3. Spain Gastric Cancer Market, Segmentation By Treatment, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

21. Eastern Europe Gastric Cancer Market

• 21.1. Eastern Europe Gastric Cancer Market Overview
• 21.2. Eastern Europe Gastric Cancer Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 21.3. Eastern Europe Gastric Cancer Market, Segmentation By Diagnosis, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 21.4. Eastern Europe Gastric Cancer Market, Segmentation By Treatment, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

22. Russia Gastric Cancer Market

• 22.1. Russia Gastric Cancer Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 22.2. Russia Gastric Cancer Market, Segmentation By Diagnosis, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 22.3. Russia Gastric Cancer Market, Segmentation By Treatment, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

23. North America Gastric Cancer Market

• 23.1. North America Gastric Cancer Market Overview
• 23.2. North America Gastric Cancer Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 23.3. North America Gastric Cancer Market, Segmentation By Diagnosis, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 23.4. North America Gastric Cancer Market, Segmentation By Treatment, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

24. USA Gastric Cancer Market

• 24.1. USA Gastric Cancer Market Overview
• 24.2. USA Gastric Cancer Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 24.3. USA Gastric Cancer Market, Segmentation By Diagnosis, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 24.4. USA Gastric Cancer Market, Segmentation By Treatment, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

25. Canada Gastric Cancer Market

• 25.1. Canada Gastric Cancer Market Overview
• 25.2. Canada Gastric Cancer Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 25.3. Canada Gastric Cancer Market, Segmentation By Diagnosis, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 25.4. Canada Gastric Cancer Market, Segmentation By Treatment, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

26. South America Gastric Cancer Market

• 26.1. South America Gastric Cancer Market Overview
• 26.2. South America Gastric Cancer Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 26.3. South America Gastric Cancer Market, Segmentation By Diagnosis, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 26.4. South America Gastric Cancer Market, Segmentation By Treatment, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

27. Brazil Gastric Cancer Market

• 27.1. Brazil Gastric Cancer Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 27.2. Brazil Gastric Cancer Market, Segmentation By Diagnosis, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 27.3. Brazil Gastric Cancer Market, Segmentation By Treatment, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

28. Middle East Gastric Cancer Market

• 28.1. Middle East Gastric Cancer Market Overview
• 28.2. Middle East Gastric Cancer Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 28.3. Middle East Gastric Cancer Market, Segmentation By Diagnosis, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 28.4. Middle East Gastric Cancer Market, Segmentation By Treatment, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

29. Africa Gastric Cancer Market

• 29.1. Africa Gastric Cancer Market Overview
• 29.2. Africa Gastric Cancer Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 29.3. Africa Gastric Cancer Market, Segmentation By Diagnosis, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 29.4. Africa Gastric Cancer Market, Segmentation By Treatment, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

30. Gastric Cancer Market Competitive Landscape And Company Profiles

• 30.1. Gastric Cancer Market Competitive Landscape
• 30.2. Gastric Cancer Market Company Profiles
  • 30.2.1. F. Hoffmann La Roche Ltd. Overview, Products and Services, Strategy and Financial Analysis
  • 30.2.2. Merck And Co. Inc. Overview, Products and Services, Strategy and Financial Analysis
  • 30.2.3. AbbVie Inc. Overview, Products and Services, Strategy and Financial Analysis
  • 30.2.4. Sanofi S.A. Overview, Products and Services, Strategy and Financial Analysis
  • 30.2.5. Bristol Myers Squibb Company Overview, Products and Services, Strategy and Financial Analysis

31. Gastric Cancer Market Other Major And Innovative Companies

• 31.1. Abbott Laboratories
• 31.2. Novartis AG
• 31.3. GlaxoSmithKline Plc
• 31.4. Eli Lilly and Company
• 31.5. Amgen Inc.
• 31.6. Gilead Sciences Inc.
• 31.7. Teva Pharmaceutical Industries Ltd.
• 31.8. Boehringer Ingelheim
• 31.9. Astellas Pharma Inc.
• 31.10. Daiichi Sankyo Company Limited
• 31.11. Eisai Co. Ltd.
• 31.12. Ipsen Biopharmaceuticals Inc.
• 31.13. Ono Pharmaceutical Co. Ltd.
• 31.14. Samsung Biologics Co. Ltd.
• 31.15. Celltrion Healthcare Co. Ltd.

32. Global Gastric Cancer Market Competitive Benchmarking And Dashboard

33. Key Mergers And Acquisitions In The Gastric Cancer Market

34. Recent Developments In The Gastric Cancer Market

35. Gastric Cancer Market High Potential Countries, Segments and Strategies

• 35.1 Gastric Cancer Market In 2029 - Countries Offering Most New Opportunities
• 35.2 Gastric Cancer Market In 2029 - Segments Offering Most New Opportunities
• 35.3 Gastric Cancer Market In 2029 - Growth Strategies
  • 35.3.1 Market Trend Based Strategies
  • 35.3.2 Competitor Strategies

36. Appendix

• 36.1. Abbreviations
• 36.2. Currencies
• 36.3. Historic And Forecast Inflation Rates
• 36.4. Research Inquiries
• 36.5. The Business Research Company
• 36.6. Copyright And Disclaimer

관련자료